Table 1. Baseline characteristics of included patients.
| Variable | Patients with stable tumors (n = 28) | Patients with tumor increased (> 3 mm) (n = 6) |
|---|---|---|
| Age at diagnosis, y | ||
| Median (range) | 41 (15-79) | 42 (26-79.7) |
| <60 y.o. (n) | 30 (88) | 5 (83) |
| Sex, n (%) | ||
| Female | 29 (85) | 6 (100) |
| Male | 5 (15) | 0 |
| Citology, n (%) | ||
| Bethesda category V | 10 (30) | 1 (17) |
| Bethesda category VI | 24 (70) | 5 (83) |
| Surveillance modality (%) | ||
| Prospective | 24 (70) | 4 (67%) |
| Retrospective | 10 (30) | 2 (33%) |
| Extent of active surveillance (months) | ||
| Median (range) | 42 (7-120) | 41,8 (24-84) |
| Tumor size (%) ≤ 1 cm 1.1-1.5 cm | 24 (70) 10 (30) | 1 (17) 5 (83) |
| History of autoimmune thyroid disease, n (%) | ||
| None | 19 (56) | 5 (83) |
| Autoimmune thyroiditis | 13 (38) | 1 (17) |
| Subacute thyroiditis | 1 (3) | 0 |
| Graves’ disease | 1 (3) | 0 |
| TSH levels (mUI/mL) | ||
| Median (range) | 0.63 (0.52-1.5) | 1.03 (0.8-1.2) |
| Levothyroxine treatment (%) | ||
| Yes | 36 | 0 |
| No | 64 | 100 |
SD: standard deviation; n: number of patients; TSH: thyrotrophin.